Concomitant lithium and methadone treatment in a bipolar patient: a case report
DOI:
https://doi.org/10.20882/adicciones.244Keywords:
lithium, methadone, bipolar disorder, dual diagnosis, treatmentAbstract
Dual diagnosis requires complex therapeutic approaches to adapt treatment to the dual nature of the problem. It is important to understand the drug effects and the drug interactions that may be observed during the integral treatment of these pathologies. Given the scarcity of data on the effects of lithium and methadone treatment, the aim of this clinical case report is to explain the interactions produced between methadone and lithium carbonate, in a female patient with medical multi-pathology, opioid-dependent and with comorbid bipolar disorder, who was treated with both drugs. The most common adverse effects for each drug are described. Drug interactions and temporal correspondence of the two drugs, as well as their dosages, are described through review of the retrospective chart and prospective follow-up of the patient. After oneyear of follow-up the patient had experienced no interactions in the concomitant lithium and methadone treatment. It should be noted that treatment of bipolar patients with dual diagnosis is complex, and should only be carried out by experts.References
Callaly T, Trauer T, Munro L, Whelan G. Prevalence of psychiatric disorder in a methadone maintenance population. Aust N Z J Psychiatry 2002; 36: 426-427.
Torrens M, Martin-Santos R, Samet S. Importance of clinical diagnoses for comorbidity studies in substance use disorders. Neurotox Res 2006; 10: 253-261.
Mateu G, Astals M, Torrens M. Comorbilidad psiquiátrica y trastorno por dependencia de opiáceos: del diagnóstico al tratamiento. Adicciones 2005; 17 Supl 2: 111-121.
Brooner RK, King VL, Kidorf M, Schmidt CW, Bigelow GE. Psychiatric and substance use comorbidity among treatment seeking opioid abusers. Arch Gen Psychiatry 1997; 54: 71-80.
Krausz M, Verthein U, Degkwitz P. Prevalence of psychiatric disorders in opiate dependent patients in contact with the drug treatment system. Nervenarzt 1998; 69: 557-567.
Fernández Miranda JJ, González García-Portilla M, Sáiz Martínez P, Gutiérrez Cienfuegos E, Bobes García J. Influencia de los trastornos psiquiátricos en la efectividad de un programa de mantenimiento prolongado con metadona. Actas Esp Psiquiatr 2001; 29: 228-232.
Rodríguez-Llera MC, Domingo-Salvany A, Brugal MT, Silva TC,
Sánchez-Niubó A, Torrens M, ITINERE Investigators. Psychiatric comorbidity in young heroin users. Drug Alcohol Depend 2006; 84: 48-55.
Weiss RD, Kolodziej M, Griffin ML, Najavits LM, Jacobson LM, Greenfield SF. Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence. J Affect Disord 2004; 79: 279-283.
Brady KT, Sonne SC. The relationship between substance abuse and bipolar disorder. J Clin Psychiatry 1995; 56 Supl 3: 19-24.
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-8.
Brown ES, Suppes T, Adinoff B, Thomas NR. Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord 2001; 65: 105-115.
Maremmani I, Perugi G, Pacini M, Akiskal Hs. Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. J Affect Disord 2006; 93: 1-12.
Freeman MP, Wiegand C, Gelenberg AJ. Litio. En: Schatzberg AF, Nemerof CB, Editores. Tratado de psicofarmacología. 13 ed. Barcelona: Masson; 2006. p. 597-617.
Baldessarini RJ, Tarazi FI, Editors. Drugs and the treatment of psychiatric disorders: psychosis and mania. Goodman and Gilman’s. The Pharmacological Basis of Therapeutics, 10 Ed. New York: McGraw-Hill, 2001. p. 485-520.
Birch NJ, Hullin RP. Lithium and the kidney. Br Med J 1980; 280:
-9.
Keck PE Jr, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin
Psychiatry 2002; 63 Supl 4: 3-11.
Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a metaanalysis. Acta Psychiatr Scand 2001; 104: 163-72.
Colom J, Duro P, Editores. Tractament de manteniment amb metadona. Manual de pràctica clínica. Barcelona: Generalitat de Catalunya. Departament de Salut; 2005.
Vazquez V, Gury C, Laqueille X. Méthadone: de la pharmacocinétique
à la pharmacologie clinique. Encéphale 2006; 32 (4 Pt 1): 478-86.
Eap CB, Broly F, Mino A, Hämmig R, Déglon JJ, Uehlinger C, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001; 21: 229-34.
Moreno Brea MR, Rojas Corrales O, Gibert-Rahola J, Mico JA. Interacciones medicamentosas de metadona con fármacos activos del SNC. Actas Esp Psiquiatr 1999; 27: 103-10.
Mannisto PT, Saarnivaara L. Effect of lithium on the analgesia caused
by morphine and two antidepressants in mice. Pharmacology 1972;8: 329-35.
Staunton DA, Deyo SN, Shoemaker WJ, Ettenberg A, Bloom FE. Effects of chronic lithium on enkephalin systems and pain responsiveness. Life Sci 1982; 31: 1837-40.
Flemenbaum A, Cronson AJ, Weddige RL. Lithium in opiate abuse: a theoretical approach. Comprehensive Psychiatry 1979; 20: 91-9.
Abrahamson JR. Use of lithium to control drug abuse. Am J Psychiatry 1983; 140: 1256.
Liebman JM, Segal DS. Lithium differentially antagonises selfstimulation
facilitated by morphine and (+)-amphetamine. Nature 1976; 260: 161-3.
Tomkiewicz M, Steinberg H. Lithium treatment reduces morphine
self-administration in addict rats. Nature 1974; 252: 227-9.
Dehpour AR, Farsam H, Azizabadi-Farahani M. Inhibition of the
morphine withdrawal syndrome and the development of physical dependence by lithium in mice. Neuropharmacology 1994; 34: 115-21.
Pani PP, Agus A, Gessa GL. Methadone as a mood stabilizer. Heroin Add & Rel Clin Probl 1999; 1: 43-44.
Baño MD, Micó JA, Agujetas M, López ML, Guillén JL. Eficacia del
antipsicótico olanzapina en el tratamiento del abuso de cocaína en pacientes en mantenimiento con metadona. Interacción en los niveles plasmáticos. Actas Esp Psiquiatr 2001; 29: 215-20.
Gerra G, Di Petta G, D’Amore A, Iannotta P, Bardicchia F, Falorni F, et al. Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clin Neuropharmacol. 2007; 30: 127-35.
Martínez-Raga J, Sabater A, Perez-Galvez B, Castellano M, Cervera
G. Add-on gabapentin in the treatment of opiate withdrawal. Prog
Neuropsychopharmacol Biol Psychiatry 2004; 28: 599-601.
Kharlamb V, Kourlas H. Edema in a patient receiving methadone
for chronic low back pain. Am J Health Syst Pharm 2007; 64: 2557-60.
Cardoso F. Chorea: non-genetic causes. Curr Opin Neurol 2004;
: 433-6.
Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142: 1259-64.
Verebey K, Kogan MJ, Mule SJ. Phencyclidine-induced stereotype
in rats: effects of methadone, apomorphine, and naloxone. Psychopharmacology (Berl) 1981; 75: 44-7.
Maremmani I, Pacini M, Perugi G, Deltito J, Akiskal H. Cocaine abuse and the bipolar spectrum in 1090 heroin addicts: clinical observations and a proposed pathophysiologic model. J Affect Disord 2008; 106: 55-61.
Levinson I, Galynker II, Rosenthal RN. Methadone withdrawal
psychosis. J Clin Psychiatry 1995; 56: 73-6.
Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999; 60: 733-40.
Maremmani I, Zolesi O, Aglietti M, Marini G, Tagliamonte A, Shinderman M, et al. Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis 2000; 19: 29-41.
Gaudiano BA, Uebelacker LA, Miller IW. Impact of remitted substance use disorders on the future course of bipolar I disorder: Findings from a clinical trial. Psychiatry Res 2008; 160:63-71.
Grunze H, Amann B, Dittmann S, Walden J. Clinical relevance and
treatment possibilities of bipolar rapid cycling. Neuropsychobiology
; 45 Supl 1: 20-6.
Casas M, Franco MD, Goikoelea JM, Jiménez-Arriero MA, Martínez-Raga J, Roncero C, et al. Trastorno bipolar asociado al uso de sustancias adictivas (patología dual). Revisión sistemática de la evidencia científica y consenso entre profesionales expertos. Actas Esp Psiquiatr 2008; 36: 350-61.
